☆ 4.7 Article

High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL

LEUKEMIA (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing

Axel Kuenstner et al.

Summary: This study investigates the mutational landscape of high-grade B-cell lymphoma accompanied with double/triple-hit MYC and BCL2 and/or BCL6 rearrangements (HGBLDH/TH). The study finds oncogenic mutations in several signaling pathways and reveals the mutational relationship between several types of lymphomas. Additionally, the study uncovers molecular divergence between BCL2 and BCL6 rearranged HGBL-DH cases.

HAEMATOLOGICA (2022)

Add to Collection

Article Pathology

Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge

Mahsa Khanlari et al.

Summary: The study demonstrated significant differences in immunophenotypic, cytogenetic, and molecular features between blastoid-HGBL and B-ALL. The scoring system developed based on distinctive features showed high sensitivity and specificity for the classification of blastoid lymphoid tumors presenting initially in the bone marrow.

MODERN PATHOLOGY (2022)

Add to Collection

Article Hematology

Comparison Between CHOP and DAEPOCH with or Without Rituximab in Adult High Grade B Cell Lymphoma, Not Otherwise Specified; A Retrospective Study From a Tertiary Cancer Hospital in South India

Lalatendu Moharana et al.

Summary: Comparing the treatment outcomes of HGBL, NOS patients with CHOP and DAEPOCH regimens, it was found that DAEPOCH resulted in better PFS and OS, despite higher toxicity. HGBL, NOS is a heterogeneous group of aggressive lymphoma associated with early relapse in nearly half of the cases.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2022)

Add to Collection

Article Pathology

Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms A Multiparameter Study of a Rare and Aggressive Entity

Shweta Bhavsar et al.

Summary: In the current classification of the World Health Organization, TdT expression in high grade/large cell B-cell lymphoma indicates B-lymphoblastic lymphoma/leukemia. However, there are reports of TdT expression in mature LBCL or following mature B-cell neoplasms. The frequency, categorization, clinicopathologic features, molecular landscape, and relationship to classic B-LBL of TdT(+) LBCL remain to be better defined. In this study, TdT expression was assessed in 258 LBCL and correlated with cytologic, phenotypic, and cytogenetic findings. Mutational analysis, review of prior biopsies, and assessment of clinical associations were performed in 6 cases with >10% TdT(+) cells. The 6 TdT(+) LBCL cases were blastoid-appearing, CD34(-), MYC+, BCL2(+), and had MYC rearrangements (R) (5/6 with BCL2 and/or BCL6-R). They had a prior TdT(-) LBCL and/or follicular lymphoma and all had an aggressive course. The mutational profiles were more like those reported in germinal center B-cell type-diffuse LBCL rather than B-LBL. The clinicopathologic and cytogenetic features of these 6 cases were similar to those found in a meta-analysis that included additional cases of TdT(+) LBCL or B-LBL following follicular lymphoma. Thus, TdT(+), CD34(-) large B-cell neoplasms with MYC rearrangements and often a double hit are rare, frequently a transformational event and aggressive but are distinct from classic B-LBL.

AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)

Add to Collection

Review Hematology

Defining and treating high-grade B-cell lymphoma, NOS

Adam J. Olszewski et al.

Summary: High-grade B-cell lymphoma, not otherwise specified (HGBL, NOS) is a recently introduced diagnostic category for aggressive B-cell lymphomas. It includes rare and heterogeneous tumors that cannot be classified as other well-defined lymphoma subtypes. Improved molecular diagnostics are needed to improve outcomes and treatment for patients.

BLOOD (2022)

Add to Collection

Article Hematology

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo et al.

Summary: Since 1994, the classification of lymphoid neoplasms has been continuously updated through international efforts, with recent progress driven by genomic studies. This proposal presents the International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors, which has refined diagnostic criteria and incorporated new insights from genomics.

BLOOD (2022)

Add to Collection

Article Oncology

BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival

Sonia Gonzalez de Villambrosia et al.

Summary: High Grade B Cell Lymphoma, NOS and High Grade B Cell Lymphoma with Dual Hit or Triple Hit were recently reclassified in the 2016 WHO classification. This study found that HGBCL NOS had better response to first line treatment compared to HGBCL with DH/TH, and only the presence of BCL2 translocation significantly affected PFS. Other clinical features were similar between the two categories, and both high grade and DLBCL morphological patterns showed equivalent PFS and OS.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Review Oncology

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

Rita Alaggio et al.

Summary: This article provides an overview of the upcoming 5th edition of the World Health Organization classification of lymphoid tumors, highlighting changes from the previous edition such as reorganization of entities, modification of nomenclature, revision of diagnostic criteria, deletion of entities, introduction of new entities, and inclusion of tumor-like lesions.

LEUKEMIA (2022)

Add to Collection

Article Hematology

MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma

Lifu Wang et al.

Summary: Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and has shown to be a negative prognostic factor for patients. Patients with MYC-EC have an intermediate overall survival compared to MYC-R and MYC-NL patients, especially those with blastoid/pleomorphic morphology.

HAEMATOLOGICA (2021)

Add to Collection

Meeting Abstract Hematology

High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers

Adam Zayac et al.

BLOOD (2021)

Add to Collection

Article Biochemical Research Methods

Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy

Li Zhang et al.

Summary: Neoadjuvant immunotherapy can induce immune responses within the tumor microenvironment, and gene expression can be used to assess these responses. This study aimed to evaluate the concordance of immune-related gene expression data across different platforms and panels. While a high level of consistency was observed, there were subsets of genes that showed differential expression across the panels. Despite these differences, the HTG PIP panel showed the best classification performance among the three panels.

JOURNAL OF IMMUNOLOGICAL METHODS (2021)

Add to Collection

Letter Hematology

A 70% cut-off for MYC protein expression in diffuse large B-cell lymphoma identifies a high-risk group of patients

Marita Ziepert et al.

HAEMATOLOGICA (2020)

Add to Collection

Article Oncology

High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases

Jiayin Li et al.

CANCER MANAGEMENT AND RESEARCH (2020)

Add to Collection

Article Pathology

High-grade B-cell lymphomas with TdT expression: a diagnostic and classification dilemma

Chi Young Ok et al.

MODERN PATHOLOGY (2019)

Add to Collection

Article Pathology

Reliable Gene Expression Profiling from Small and Hematoxylin and EosineStained Clinical Formalin-Fixed, Paraffin-Embedded Specimens Using the HTG EdgeSeq Platform

Zhenhao Qi et al.

JOURNAL OF MOLECULAR DIAGNOSTICS (2019)

Add to Collection

Article Hematology

The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH

Laura K. Hilton et al.

BLOOD (2019)

Add to Collection

Letter Hematology

Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

Anna Stengel et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Add to Collection

Letter Hematology

Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

Solene M. Evrard et al.

HAEMATOLOGICA (2019)

Add to Collection

Article Oncology

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma

Daisuke Ennishi et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy

Chulin Sha et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Cell Biology

Comparison of Reproducibility, Accuracy, Sensitivity, and Specificity of miRNA Quantification Platforms

Paula M. Godoy et al.

CELL REPORTS (2019)

Add to Collection

Article Pathology

MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas

Wenting Huang et al.

MODERN PATHOLOGY (2018)

Add to Collection

Review Hematology

Advances in pathological understanding of high-grade B cell lymphomas

Shaoying Li et al.

EXPERT REVIEW OF HEMATOLOGY (2018)

Add to Collection

Article Oncology

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Daniel J. Landsburg et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Pathology

Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma

Andres E. Quesada et al.

MODERN PATHOLOGY (2017)

Add to Collection

Article Oncology

Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma

Shaoying Li et al.

ONCOTARGET (2016)

Add to Collection

Article Pathology

B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas

Shaoying Li et al.

MODERN PATHOLOGY (2015)

Add to Collection

Article Hematology

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich et al.

BLOOD (2014)

Add to Collection

Article Hematology

Double hit lymphoma: the MD Anderson Cancer Center clinical experience

Yasuhiro Oki et al.

BRITISH JOURNAL OF HAEMATOLOGY (2014)

Add to Collection

Article Hematology

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

Sietse M. Aukema et al.

HAEMATOLOGICA (2014)

Add to Collection

Article Education, Scientific Disciplines

Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC

Steven H. Swerdlow

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)

Add to Collection

Article Oncology

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Tina Marie Green et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Oncology

Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Nathalie A. Johnson et al.

JOURNAL OF CLINICAL ONCOLOGY (2012)

Add to Collection

Article Pathology

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): an aggressive disease with heterogeneous histology, germina center B-cell immunophenotype and poor outcome

Shaoying Li et al.

MODERN PATHOLOGY (2012)

Add to Collection

Article Hematology

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

CP Hans et al.

BLOOD (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.